Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Avidity Biosciences
Biotech
Atrium arises from Avidity buyout with $270M, preclinical assets
Atrium hopes to have two siRNA candidates for genetic cardiac diseases in the clinic by 2027.
Darren Incorvaia
Feb 27, 2026 11:05am
Why Novartis CEO was willing to pay top dollar for Avidity
Nov 20, 2025 4:37am
Novartis pays $12B for late-stage dystrophy biotech Avidity
Oct 26, 2025 4:01pm
Avidity's latest DMD data drop assuages safety concerns: analyst
Mar 17, 2025 2:00pm
Analysts dig into Avidity's DMD win, revealing nuances in data
Aug 12, 2024 9:24am
Avidity therapy shows possible benefit in muscular dystrophy
Jun 12, 2024 7:00am
